Day: June 11, 2021

FARMINGTON HILLS, Mich., June 11, 2021 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on development and commercialization of therapies for the treatment of several eye disorders, today announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted June 4, 2021. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes. “Inclusion in the Russell...

BEIJING, June 11, 2021 (GLOBE NEWSWIRE) — How to take action on carbon neutrality was discussed during the 2021 China Entrepreneurs Forum. Panelists shared their opinions on their solution to energy transition and carbon emission reduction. Alex Ju, Founder and CEO of Chindata Group, a leading hyperscale data center solution provider in emerging markets, delivered his “Super Energy Complex” proposal by establishing new energy scenarios with data centers as the driver in the fields such as municipal heating, new energy vehicle charging, cold chain logistics, ecological agriculture, and snow sports. “The operation of data centers is a process of energy transferring from cold to heat and vice versa. Then we can think about how to take advantage of those resource slack to further improve the efficiency of energy consumption. The cooling...

VANCOUVER, British Columbia, June 11, 2021 (GLOBE NEWSWIRE) — Eldorado Gold Corporation (“Eldorado” or “the Company”) is pleased to announce that all director nominees, as listed in the Management Proxy Circular dated April 27, 2021, were elected as directors of Eldorado at the Company’s Annual Meeting of Shareholders (the “Meeting”) held virtually on June 10, 2021.Election of Directors      Directors Votes For Votes Withheld OutcomeGeorge Albino 89,608,334   1,629,121   Elected98.21%   1.79%  George Burns  90,597,246   640,220   Elected99.30%   0.70%  Teresa Conway 90,540,695   696,770   Elected99.24%   0.76%  Catharine Farrow 90,432,623   804,842   Elected99.12%   0.88%  Pamela Gibson 89,348,846   1,888,620   Elected97.93%   2.07%  Judith Mosely 90,482,619   754,847   Elected99.17%   0.83%  Steven...

Press releaseSchindellegi – SwitzerlandTrifork has agreed with the existing owners of the Fintech company YoungMoney ApS to invest in the company and receive an ownership of 25% in the company. Young Money ApS is currently delivering the Young Money App universe to children in Denmark. Currently this App solution has approximately 40,000 users and just about 20,000 transactions are completed each month. The company plans to deliver innovative digital products and services to banks, both in Denmark and internationally. The products will be targeted to both private and business customers. “Joining Young Money as an owner is an example of Trifork’s philosophy about developing new products and solutions in very close relationship with our customers. Fintech is currently growing very fast and we want to continue developing new innovative...

BALA CYNWYD, Pa., June 11, 2021 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar Therapeutics, will present and participate in virtual 1×1 investor meetings at the JMP Securities Life Sciences Conference taking place from June 16-17, 2021. See below for more details.Presentation Format: Fireside chatDate: June 16, 2021Time: 2:00 PM ETAbout Larimar Therapeutics Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in...

Figure 1Gameta Project drill hole plan. Refer Figure 2 for detailed view of Cross Section 25 showing Ag intersection.Figure 2Cross section 25 showing results from current drill program. Unlabelled holes are historical RC drill holes.Figure 3Cross section 27 showing results from current drill program. Unlabelled holes are historical RC drill holes.About AdytonMap showing the location of Adyton’s Papua New Guinea exploration projects relative to significant PNG gold projects.BRISBANE, Australia, June 11, 2021 (GLOBE NEWSWIRE) — Adyton Resources Corporation (TSX Venture: ADY) (“Adyton”) is pleased to report that multi-element analysis of drill core samples from the diamond drilling program at its 100% owned Gameta Gold Project have confirmed the potential for the...

Announcement no. 12/2021 Upgraded profit guidance for 2021 As a result of a highly satisfactory and better-than-expected performance in the past few months, Alm. Brand upgrades its profit guidance for 2021 to DKK 700-750 million from the previous guidance of a profit of DKK 650-700 million. For Non-life Insurance, the guidance is lifted by DKK 100 million to a profit of DKK 725 million before tax, driven by a generally favourable trend in underlying insurance operations. However, growth has not materialised quite as soon after the reopening of society as had been expected, resulting in growth expectations of 1.5-2.0% for the full year, with continued focus on generating profitable growth. The guidance for Life Insurance is unchanged at a pre-tax profit of DKK 100 million and growth in regular premium payments of 3-4%. The guidance for...

Verkkokauppa.com Oyj                MANAGERS’ TRANSACTIONS                June 11, 2021 at 14:00 EET Verkkokauppa.com Oyj has received a notification from Samuli Seppälä, Verkkokauppa.com Oyj’s Board member, of a transaction made with Verkkokauppa.com Oyj’s financial instrument, according to the Article 19 of EU Market Abuse Regulation. Detailed information about the transaction is given here under.Person subject to the notification requirementName: Seppälä, SamuliPosition: Member of the Board____________________________________________ Issuer: Verkkokauppa.com OyjLEI: 743700QZE6B52SHHTV75 Notification type: INITIAL NOTIFICATIONReference number: 743700QZE6B52SHHTV75_20210611102949_4____________________________________________ Transaction date: 10 June 2021Instrument type: SHAREISIN: FI4000049812Nature of the transaction: DISPOSAL Transaction...

LOS ANGELES and TORONTO, June 11, 2021 (GLOBE NEWSWIRE) — The Tinley Beverage Company (CSE:TNY, OTC:TNYBF) (“Tinley’s” or “Company”) is pleased to announce that it has closed a C$2.4 million private placement to advance its co-packing and branded product growth. Closing occurred on June 10, 2021. The Company continues to make capital investments to expand the scope of product formulation types and packaging formats that can be produced at its cannabis beverage manufacturing facility in Long Beach, California. The mini line and bottling lines have significant bookings in June and July, including third-party brands as well as manufacturing additional inventory of the Company’s own products to fulfill dispensary demand. The commissioning of the canning line is currently expected to be completed this month, with initial clients currently...

TORONTO, June 11, 2021 (GLOBE NEWSWIRE) — Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of innovative Anti-Cancer Therapy (“ACT”) technologies intended to safely and effectively destroy various cancers, bacteria and viruses, while preserving patient Quality Of Life (“QOL”) announced today the launch of the seventh US-based Clinical Study Site (“CSS”); specifically, the University of Chicago Medicine (“UChicago Medicine”). UChicago Medicine has successfully received Institutional Review Board (“IRB”) approval allowing them to commence enrollment and treatment of patients in Theralase®’s pivotal Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study (“Study II”). Study II is focused...